How On Planet Earth

An in-depth metabolic and clinical analysis of #Enobosarm (MK-2866)—a selective androgen receptor modulator (SARM) transitioning from fitness subcultures to the vanguard of clinical medicine through $Veru Inc.'s strategic clinical alliance with Novo Nordisk $NVO howonplanetearth.com/enobosarm/

@PeptideList $VERU 's Enobosarm fixes this, 100% muscle preservation at 3mg. They also just secured a supply agreement of WeGovy from Novo Nordisk.

GLP-1 weight loss changes the number on the scale faster than it changes body image, muscle quality, habits, and monitoring. The better conversation is not "did it work?" Yes it works better than anything that’s ever existed before. It is: what changed, what was preserved, and what still needs follow-up? Continued care treatment with a provider that understands peptides.

@ZachMcGrew In what format? Oral form is great, with the caveat that since it's not local, I notice CNS effects. Both enhanced music appreciation, but also emotional blunting and loss of appetite. Many great studies of BPC-157 exist being used to combat amphetamine damage for this reason.

I take so much BPC-157 if it ever shows it has any negative impact I’ll surely know

@eliterecomp On June 2, 2026, $VERU announced a landmark clinical supply agreement with Novo Nordisk. They are combining Wegovy (semaglutide) with Enobosarm (MK-2866), a first-in-class Selective Androgen Receptor Modulator (SARM), to create an anabolic shield for muscle.

1/ Semaglutide (Ozempic/Wegovy) GLP-1 only. One receptor target. Great for blood sugar control and appetite suppression. Solid starting point for most people. Weekly injection. Well studied. The baseline everyone gets compared to. It works. It's just not the ceiling.

GLP-1 Showdown 🧵 Semaglutide vs. Tirzepatide vs. Retatrutide Three compounds. Three different levels of firepower. If you're confused about which is right for you — this is the thread. 👇

@DrCamRx $VERU solves this. Kudos to Novo Nordisk, excellent positioning.

PREDICTION: When Lilly releases its DEXA data for its Phase 3 clinical trial on Retatrutide, it will show that there is far more muscle loss on Retatrutide vs. Tirzepatide and most of the additional weight lost is simply muscle loss, thus negating its supposed superiority.

@NotA_Bull $VERU Veru's primary clinical asset, enobosarm, recently secured a major trial partnership with Novo Nordisk to be paired with blockbuster GLP-1 drugs like Wegovy to preserve patients' lean muscle mass during weight loss.

I have $15,500 to buy the dip. Which stocks should I buy?

[Tweet 9/9] The partnership between Veru and Novo Nordisk is a paradigm shift. The future of weight loss isn't just about getting lighter—it is about keeping the muscle to enjoy a longer, stronger healthspan. Read the full clinical and financial deep dive here: 👉 howonplanetearth.com/enobosarm/

[Tweet 8/9] For investors, $VERU is a highly asymmetric biotech bet. Novo Nordisk secured a Right of First Negotiation (ROFN) for Enobosarm. If the Phase 2b PLATEAU trial hits its endpoints, Novo is legally positioned to snap up Veru's IP to block competitors like Eli Lilly.

The Muscle Preservation Revolution: How Enobosarm ($VERU ) and Novo Nordisk are Redefining the Future of Obesity Medicine #Enobosarm #MK2866 #NVO #VERU howonplanetearth.com/enobosarm/

@BK_McCallum @FirstSquawk What is the case?

@FirstSquawk I'd wait to make sure they're not wrapped up in the grand conspiracy case.

CrowdStrike sees its price target lifted to $675 from $400 by Canaccord Genuity.

@_9th_Life_ Check out $VERU with Enobosarm for this use case. Muscle preservation during weight loss with GLPs.

Hot take: Eli Lilly pushes trenbolone through FDA approval within 5 years as a lean mass preservation therapy alongside GLP1s. We will see GLP-7 + Trenovia (cool brand name I came up with) become the new meta. Remember who told you. $LLY

@GAndersonTrades It could be epic for a short-term directional trade. Unfortunately, it's not a buy-and-hold asset due to the daily reset.

THEY MADE A 2x $SNDK SHORT ETF 😭💀 This will be a GENRATIONAL play in due time

@hubermanlab Oral peptides and small molecules for sure. I'm surprised GLPs took off given their administration, but maybe the overlap in people who use insulin injections bridged the gap for the jab requirement.

I predict peptides will change everything re public health discourse for health & disease. B/c they’re closer to medications (in many cases actual medications!) than supplements but they entered the picture in supplement-like fashion. HRT went the other direction. Get educated.